electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom

Rhea-AI Summary

electroCore, a bioelectronic medicine company, has launched an e-commerce shop in the UK for its gammaCore Sapphire™ device, designed to treat menstrual migraines. The online platform allows patients to complete a healthcare questionnaire, receive product delivery, and receive training via video calls. Karly Hoggard, Director of Global Commercial Development, emphasized the importance of accessibility for women suffering from migraines, noting that 60% of them experience menstrual-related symptoms. The gammaCore device is FDA cleared and CE-marked for various headache treatments.

Positive

• Launch of e-commerce shop in the UK enhances product accessibility.
• Targeting menstrual migraine treatment aligns with market demand (60% of women report menstrual migraines).
• Users can complete assessments and receive training remotely, improving customer experience.

Negative

• None.

ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdom. The site, which can be found at www.gammacore.co.uk, requires patients to complete a healthcare questionnaire in order to purchase a gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) device online.

The first product launched on the platform is designed to treat menstrual migraine, supporting the 60% of women who report migraine symptoms associated with their menstrual cycle. This platform will allow patients to experience a fully virtual experience by completing an online clinical assessment, having product delivered to their door, and being trained via video calls with a member of the UK customer service team.

“We want to make gammaCore more accessible to patients looking to better manage their primary headache conditions. With an estimated 70% of migraineurs being female, the specificity of menstrual migraine is a natural starting point in a new chapter for our business within  the online market. We have created a simple assessment process with full clinician oversight offering ongoing customer care as required,” stated Karly Hoggard, Director of Global Commercial Development at electroCore. “Many women suffering from migraine symptoms each month expect to live with such symptoms, impacting daily life, work, family and social commitments. We are excited to offer a clinically proven option women looking for solutions to treat their primary headaches, and through this platform we hope to empower people to take ownership of their conditions and regain control.”

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About gammaCore^TM
gammaCore^TM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

• Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
• Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
• Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

• Adolescent patients with congenital cardiac issues
• Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
• Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
• Pediatric patients (less than 12 years)
• Pregnant women
• Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

For more information, please visit www.gammacore.co.uk.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in the UK (including its e-commerce initiative) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

FAQ

What is the purpose of electroCore's new e-commerce shop launched in the UK?

The e-commerce shop allows patients to purchase the gammaCore Sapphire™ device online, primarily targeting menstrual migraines.

How does the gammaCore Sapphire™ device help patients?

The gammaCore Sapphire™ device is designed to treat various types of headaches, including menstrual migraines, through non-invasive vagus nerve stimulation.

What percentage of women suffer from menstrual migraines according to electroCore?

ElectroCore states that 60% of women report migraine symptoms associated with their menstrual cycle.

Is gammaCore cleared for use in the UK?

Yes, gammaCore is CE-marked in the European Union for the treatment of various primary headaches.

What is the significance of electroCore's launch date for the e-commerce platform?

The launch occurred on December 15, 2021, marking a strategic expansion into the online market for electroCore.